Breaking News

Apollo Endosurgery announced that the endoscopic sleeve gastroplasty procedure was featured in a 2022 Top 10 Paper at the International Federation for the Surgery of Obesity and Metabolic Disorders 2022 World Congress, held August 23-27 in Miami. Dr. Brandon VanderWel, Bariatric & Metabolic Surgeon at EVIVA in Seattle, Washington, presented the paper entitled "Endoscopic Sleeve Gastroplasty Complements a Bariatric Surgery Practice". The paper is a retrospective review aimed at measuring the impact of integrating the ESG procedure into a bariatric surgery program in a community setting. Procedural volumes from 2020-2021 and clinical outcomes at 12 months were reported. Highlights include: Upon offering the ESG procedure, EVIVA received 469 new patient consults specific to ESG procedure over a two-year period; 197 patients underwent an ESG procedure and 107 patients received a laparoscopic sleeve gastrectomy. In these patients undergoing ESG, the total body weight loss at 12 months was 24% and the excess body weight loss was 75%. The rate of serious adverse events was 1%. In patients with hypertension, 45% were found to be in remission, 20% demonstrated improvement, and 35% demonstrated no change in hypertension at 12 months. In patients with diabetes, 55% were found to be in remission, 33% demonstrated improvement, and 11% demonstrated no change at 12 months.

Apollo Endosurgery announced the electronic publication of the landmark Multi-center ESG Randomized Interventional Trial Study in The Lancet. The MERIT study is a multi-center, prospective randomized clinical trial evaluating the safety and effectiveness of the Endoscopic Sleeve Gastroplasty procedure, a minimally invasive, endoscopic weight loss procedure performed with Apollo's Endosurgery's OverStitch Endoscopic Suturing System.In the study, patients with Body Mass Index greater than or equal to30 and less than or equal to40 kg/m were randomized to treatment with ESG and lifestyle modification or to a control group which involved lifestyle modification alone. At the conclusion of the primary end point, qualifying patients in the control group were allowed to cross-over to ESG if they met certain conditions. Nine US centers participated in the study, representing both gastroenterology and bariatric surgery practices from academic and community settings. One hundred and fifty-seven subjects completed the study through 52 weeks of follow-up. Seventy-two control patients crossed over to treatment at 52 weeks, and both groups were followed an additional 52 weeks. Key results for patients undergoing ESG include: 49.2% excess body weight loss at 12 months in the treatment group; 16.3% average total body weight loss in the responder group; 68.3% of responders maintained at least 25% EWL at 104 weeks; Improvements in quality of life, eating behaviors, and depression. Three ESG patients experienced a device or procedure related serious adverse event, all of which resolved and did not require intensive care or surgical intervention.

Apollo Endosurgery announced the marketing authorization of the Apollo ESG, Apollo ESG Sx, Apollo REVISE and Apollo REVISE Sx Systems through the U.S. Food and Drug Administration's De Novo Classification process. These are the first and only devices authorized by the FDA for endoscopic sleeve gastroplasty and endoscopic bariatric revision.

Apollo Endosurgery announced that Sharon O'Keefe has joined the company's Board of Directors, effective July 6, 2022. O'Keefe was President of the University of Chicago Medical Center from 2011 to 2020, overseeing a network of physicians and clinics with 10,000 employees and annual operating revenue in excess of $2 billion. Apollo also announced that Rick Anderson has retired from the Apollo Board of Directors, effective immediately. Mr. Anderson, Chairman of Revival Healthcare Capital, has served as a member of the Apollo Board of Directors since 2013.